Fernando is an Investment Director at Endeavour Vison focused on medical technology and digital health investments, with particular focus in orthopedics, robotics, ophthalmology, ENT, GI and diagnostics. During his nearly 3 years with the company, he has led work on multiple sector reviews, led our deal screening efforts and participated in a number of diligence projects on potential deals. Fernando represents Endeavour Vision as board observer for SOPHiA GENETICS. He was on the deal team for our investments in SOPHiA GENETICS, Lumeon and CeQur.
Prior to joining Endeavour Vision Fernando was an Engagement Manager at McKinsey & Company. There, he led numerous business strategy and organizational projects including therapeutic-area strategy, merger management, process optimization, operating model re-design, corporate due-diligence and market access and launch preparation. Fernando worked across multiple geographies, including Switzerland, France, Germany, Belgium, UK, US and Brazil and sectors such as diabetes, specialty pharmaceuticals, infectious disease, wound care, surgical instruments, orthopedics and dental. Before McKinsey, Fernando led the development of several orthopaedic trauma solutions at Stryker Orthopaedics R&D in Switzerland – focusing on upper trauma and extremities.
Fernando holds an MEng degree in Biomedical and Mechanical Engineering from Imperial College London and the Swiss Federal Institute of Technology (ETH) Zürich. His Masters’ thesis was in cardiovascular fluid mechanics of stented arteries.